HEXO:CA:TSX-HEXO Corp.

EQUITY | Drug Manufacturers | Toronto Stock Exchange

Last Closing

CAD 7.42

Change

+0.06 (+0.82)%

Market Cap

CAD 1.80B

Volume

2.10M

Analyst Target

CAD 10.69
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-06-18 )

Largest Industry Peers for Drug Manufacturers

ETFs Containing HEXO:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (Toronto Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 57.54% 100% F 97% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 57.54% 100% F 97% N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A F
Risk Adjusted Return N/A N/A N/A N/A F
Market Capitalization 1.80B 72% C 90% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers) Ratio vs. Market (Toronto Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -46.38 76% 94%
Price/Book Ratio 4.22 24% 11%
Price / Cash Flow Ratio -10.75 71% 96%
Price/Free Cash Flow Ratio -9.16 65% 81%
Management Effectiveness  
Return on Equity -8.44% 71% 21%
Return on Invested Capital -9.84% 53% 13%
Return on Assets -8.08% 59% 16%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector